Zhaoke Ophthalmology (formerly China Ophthalmology Focus Limited) develops and manufactures ophthalmic drugs, including proprietary products and difficult-to-manufacture generics. It has a pipeline of more than 20 products spanning pre-clinical to registration stages. The company is positioning to commercialize these products for the Chinese and ASEAN markets. Management emphasizes drug innovation and development across various ophthalmic indications to address significant unmet medical needs in China. The recent Series B financing strengthens its balance sheet to support R&D, technology development, and scaling of commercial capabilities. Company leadership has indicated the funding may help pave the way for a possible spin-off and separate listing in the future.

Total raised

$145M

Funding rounds

1

Latest round

Series B

Latest activity

Oct 2020